SelectQuote, Inc.

Informe acción NYSE:SLQT

Capitalización de mercado: US$181.6m

SelectQuote Dirección

Dirección controles de criterios 3/4

El CEO de SelectQuote es Tim Danker , nombrado en Jan 2017, tiene una permanencia de 9.33 años. compensación anual total es $3.49M, compuesta por 16% salario y 84% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.49% de las acciones de la empresa, por valor de $2.71M. La antigüedad media del equipo directivo y de la junta directiva es de 4.6 años y 4.9 años, respectivamente.

Información clave

Tim Danker

Chief Executive Officer (CEO)

US$3.5m

Compensación total

Porcentaje del salario del CEO15.97%
Permanencia del CEO9.3yrs
Participación del CEO1.5%
Permanencia media de la dirección4.6yrs
Promedio de permanencia en la Junta Directiva4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Actualización de narrativa May 04

SLQT: Reset Assumptions And Profit Margin Focus Will Support Future Upside Potential

SelectQuote’s updated analyst price target has moved to $5.00. Analysts cite adjustments to discount rates, revenue growth assumptions, profit margin expectations, and a revised future P/E of 5.76 as key drivers of the change.
Actualización de narrativa Apr 20

SLQT: Local Franchise Expansion Will Support Future P/E Re Rating

Analysts have trimmed their price targets on SelectQuote by $1 to $2, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions as the drivers of this shift. Analyst Commentary Bearish analysts cutting price targets by $1 to $2 are signaling that they see less room for upside in SelectQuote at current levels.
Actualización de narrativa Apr 06

SLQT: Reset Expectations And Pharmacy Agreement Will Support Future Upside

Analysts trimmed their SelectQuote price targets by $1 to $2, citing updated assumptions around discount rates, profit margins and long term P/E expectations that indicate a more cautious outlook on the shares. Analyst Commentary Recent research updates point to a more measured stance on SelectQuote, with price targets trimmed by $1 to $2 as analysts revisit their assumptions around discount rates, profit margins and long term P/E levels.
Actualización de narrativa Mar 22

SLQT: Pharmacy Agreement And Local Expansion Will Support Future P/E Re Rating

Analysts have trimmed their price targets on SelectQuote, with recent Street research indicating cuts of $1 and $2 to reflect revised assumptions around fair value, required return, growth and future P/E expectations. Analyst Commentary Recent Street research highlights a more cautious tone around SelectQuote, with bearish analysts trimming price targets by $1 and $2 to align with their updated assumptions on fair value, required return, growth and future P/E expectations.
Actualización de narrativa Mar 07

SLQT: Reset Expectations And New Pharmacy Agreement Will Support Future Upside

Narrative Update on SelectQuote The consensus analyst price target for SelectQuote has been reduced by a few dollars as analysts reassess their models following recent cuts of $1 and $2 highlighted in new Street research. Analyst Commentary Recent research highlights that the revised price targets reflect updated views on SelectQuote's execution risks and potential for improvement, rather than a complete shift in sentiment.
Actualización de narrativa Feb 21

SLQT: Rebased Expectations And New Pharmacy Agreement Will Support Future Upside

Analysts have trimmed their price targets on SelectQuote, with recent cuts of $1 and $2 contributing to a reduction in our fair value estimate from $4.50 to about $3.06 as they factor in adjusted growth, profitability, and risk assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price targets as reflecting updated expectations on growth and profitability rather than a fundamental change in the long term opportunity, which they still factor into their models.
Actualización de narrativa Feb 07

SLQT: Reset Assumptions And Pharmacy Agreement Will Support Future Upside Potential

Analysts have lowered their fair value estimate for SelectQuote from US$7.00 to US$5.00. This change reflects updated assumptions around higher discount rates, more modest revenue growth, slimmer profit margins and a higher future P/E multiple.
Artículo de análisis Feb 06

SelectQuote, Inc. (NYSE:SLQT) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Unfortunately for some shareholders, the SelectQuote, Inc. ( NYSE:SLQT ) share price has dived 27% in the last thirty...
Seeking Alpha Feb 01

SelectQuote Q2 Earnings Preview: Sell The Medicare Reimbursement News (Rating Downgrade)

Summary SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT’s fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins. Despite low EBITDA multiples, SLQT’s reliance on insurer commissions and worsening industry outlook justify caution ahead of Q2 earnings. Read the full article on Seeking Alpha
Actualización de narrativa Jan 23

SLQT: Future Pharmacy Agreement Will Likely Support P/E Re Rating

Analysts have trimmed their price target on SelectQuote to US$2.00 from US$2.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E. Together these factors point to a slightly adjusted risk and earnings profile without changing the headline fair value figure.
Actualización de narrativa Jan 09

SLQT: Future Profitability Shift Will Likely Unlock Deep P/E Re Rating

Analysts have reduced their price target on SelectQuote, citing a lower fair value estimate and higher discount rate, even as updated assumptions point to a higher profit margin and a much lower future P/E multiple of about 2.1x versus 26.2x previously. Valuation Changes The Fair Value Estimate was reduced from 3.0 to 2.0, indicating a lower assessed intrinsic value per share.
Actualización de narrativa Dec 19

SLQT: Expanded Senior Support Services Will Drive Future Upside Potential

Analysts have modestly raised their price target on SelectQuote, citing a slightly higher discount rate and marginally improved long term profitability assumptions. Together, these factors support an incremental increase in estimated equity value of roughly a few cents per share.
Actualización de narrativa Dec 05

SLQT: Expanded Senior Support Partnerships Will Drive Future Upside Potential

Analysts have modestly raised their price target on SelectQuote by refining their discount rate assumptions and reaffirming steady long term revenue growth and profit margin expectations. This has resulted in an updated fair value estimate that is now closer to fundamentals, though it still implies limited upside from current levels.
Actualización de narrativa Nov 21

SLQT: Expanding Senior Referral Program Will Drive Broader Long-Term Support

Analysts have lowered their price target for SelectQuote from $5.00 to $4.50 per share. They cited changes in profit margin forecasts and a higher discount rate as key factors in the revised outlook.
Artículo de análisis Nov 15

Investors Give SelectQuote, Inc. (NYSE:SLQT) Shares A 26% Hiding

The SelectQuote, Inc. ( NYSE:SLQT ) share price has fared very poorly over the last month, falling by a substantial...
Actualización de narrativa Nov 07

SLQT: Expanded Senior Services Will Unlock Long-Term Upside Despite Legal Risks

SelectQuote Price Target Lowered Amid Revised Analyst Outlook Analysts have reduced SelectQuote's price target from $5.25 to $5.00, citing updated forecasts of slower revenue growth and reduced profit margins. What's in the News SelectQuote announced a milestone partnership with Findhelp, which will enable the company to direct over 200,000 low-income seniors to free and discounted social services such as food assistance, housing aid, transportation, healthcare, and financial or legal counseling (Key Developments).
Artículo de análisis Aug 31

SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 30% But Many Are Still Ignoring The Company

SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...
Artículo de análisis Jul 16

SelectQuote, Inc. (NYSE:SLQT) Could Be Riskier Than It Looks

When close to half the companies operating in the Insurance industry in the United States have price-to-sales ratios...
Seeking Alpha Apr 28

SelectQuote: Better Fundamentals Due To Medicare Advantage Reimbursement Rate Increase (Rating Upgrade)

Summary I'm upgrading SelectQuote to a buy rating after the stock's recent sharp fall. The federal government recently approved a 5.06% reimbursement rate increase for Medicare Advantage plans, which should translate into more aggressive marketing from carriers. This will lead to stronger demand and referral fees for SelectQuote, similar to how the government's premium increase approvals helped EverQuote in the auto insurance industry. SelectQuote is a value stock at <8x forward adjusted EBITDA. Read the full article on Seeking Alpha
User avatar
Nueva narrativa Mar 26

Agent Efficiency And Medicare Services Will Transform 2025 Outlook

Improved agent efficiency and optimized marketing reduced expenses, boosting productivity and potentially enhancing margins and earnings.
Seeking Alpha Feb 11

SelectQuote: Better Prospects After Bain Deal, But Don't Rush To Buy (Upgrade)

Summary SelectQuote, Inc. skyrocketed ~30% after posting very strong Q2 results alongside the announcement of a $350 million private infusion from investors led by Bain Capital. Revenue grew 19% year-over-year to $481.1 million, with the Senior division and Health Services arm showing notable improvements in efficiency and subscriber growth. Despite a $350 million investment to reduce debt, SelectQuote remains highly leveraged, and SLQT stock's valuation is not compelling enough to warrant a bullish stance. I'd need to see a turnaround in profitability for the SelectRx division (better than the ~1% adjusted EBITDA margins seen in Q2) to consider buying SLQT stock. Read the full article on Seeking Alpha
Artículo de análisis Jan 18

SelectQuote, Inc. (NYSE:SLQT) Soars 36% But It's A Story Of Risk Vs Reward

Despite an already strong run, SelectQuote, Inc. ( NYSE:SLQT ) shares have been powering on, with a gain of 36% in the...
Artículo de análisis Nov 20

SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 29% But Many Are Still Ignoring The Company

Those holding SelectQuote, Inc. ( NYSE:SLQT ) shares would be relieved that the share price has rebounded 29% in the...
Artículo de análisis Nov 07

SelectQuote, Inc. (NYSE:SLQT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.50

It's been a pretty great week for SelectQuote, Inc. ( NYSE:SLQT ) shareholders, with its shares surging 17% to US$2.34...
Artículo de análisis Oct 03

SelectQuote, Inc. (NYSE:SLQT) Might Not Be As Mispriced As It Looks After Plunging 49%

SelectQuote, Inc. ( NYSE:SLQT ) shares have had a horrible month, losing 49% after a relatively good period beforehand...
Artículo de análisis Jul 02

SelectQuote, Inc. (NYSE:SLQT) Doing What It Can To Lift Shares

When you see that almost half of the companies in the Insurance industry in the United States have price-to-sales...
Artículo de análisis Feb 13

Investors Still Aren't Entirely Convinced By SelectQuote, Inc.'s (NYSE:SLQT) Revenues Despite 29% Price Jump

SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...
Seeking Alpha Feb 07

SelectQuote Q2: Strong Revenue Growth But Retaining My Hold Rating

Summary SelectQuote, Inc.'s fiscal Q2 revenue of $405.44 million beat estimates, marking the 6th consecutive quarter of increasing YoY revenue. The company raised its revenue guidance for FY 2024 to $1.23 billion to $1.3 billion, a 17% increase from the prior low-end guidance. Despite positive revenue growth, SelectQuote is still losing money and has a significant long-term debt load of $650 million. Read the full article on Seeking Alpha
Seeking Alpha Nov 13

SelectQuote: Insider Buying But A Significant Debt Load

Summary SelectQuote, Inc. is a small-cap online insurance broker with a stock that has had a huge decline since coming public in early 2020. However, the company has made some progress in reducing costs and the shares saw some significant insider purchases in May and September of this year. Time to buy into this improving story?  An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Artículo de análisis Nov 08

It's Probably Less Likely That SelectQuote, Inc.'s (NYSE:SLQT) CEO Will See A Huge Pay Rise This Year

Key Insights SelectQuote to hold its Annual General Meeting on 14th of November Total pay for CEO Tim Danker includes...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tim Danker en comparación con los beneficios de SelectQuote?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

US$21m

Dec 31 2025n/an/a

US$20m

Sep 30 2025n/an/a

US$22m

Jun 30 2025US$3mUS$557k

US$25m

Mar 31 2025n/an/a

-US$2m

Dec 31 2024n/an/a

-US$14m

Sep 30 2024n/an/a

-US$48m

Jun 30 2024US$3mUS$541k

-US$34m

Mar 31 2024n/an/a

-US$51m

Dec 31 2023n/an/a

-US$50m

Sep 30 2023n/an/a

-US$47m

Jun 30 2023US$3mUS$525k

-US$59m

Mar 31 2023n/an/a

-US$115m

Dec 31 2022n/an/a

-US$132m

Sep 30 2022n/an/a

-US$292m

Jun 30 2022US$3mUS$525k

-US$298m

Mar 31 2022n/an/a

-US$193m

Dec 31 2021n/an/a

-US$151m

Sep 30 2021n/an/a

US$77m

Jun 30 2021US$3mUS$500k

US$125m

Mar 31 2021n/an/a

US$143m

Dec 31 2020n/an/a

US$129m

Sep 30 2020n/an/a

-US$12m

Jun 30 2020US$4mUS$326k

-US$18m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$26m

Sep 30 2019n/an/a

US$40m

Jun 30 2019US$445kUS$305k

US$60m

Compensación vs. Mercado: La compensación total de Tim($USD3.49M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.74M).

Compensación vs. Ingresos: La compensación de Tim ha sido consistente con los resultados de la empresa en el último año.


CEO

Tim Danker (52 yo)

9.3yrs
Permanencia
US$3,487,527
Compensación

Mr. Timothy Robert Danker, also known as Tim, serves as Chief Executive Officer and Director at SelectQuote, Inc. since 2017. Mr. Danker served as the President of the SelectQuote’s Life Division from 2016...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Timothy Danker
CEO & Director9.3yrsUS$3.49m1.49%
$ 2.7m
Robert Grant
President4.6yrsUS$3.06m2.52%
$ 4.6m
Ryan Clement
Chief Financial Officer4yrsUS$2.17m0.18%
$ 332.1k
William Grant
Chief Operating Officer7.3yrsUS$2.72m2.38%
$ 4.3m
Daniel Boulware
General Counsel & Corporate Secretary6.6yrsUS$1.61m0.16%
$ 298.4k
Stephanie Fisher
Chief Accounting Officer5.8yrssin datos0.059%
$ 107.7k
Matthew Gunter
Chief Communications & Investor Relations Officerno datasin datossin datos
Ryan Souan
Chief Marketing Officer2.1yrssin datos0.071%
$ 128.1k
Alan Muney
Chief Medical Officer & Member of Healthcare Advisory Board3.8yrssin datossin datos
Joshua Matthews
President of SelectQuote Seniorno datasin datos0.35%
$ 644.7k
Sarah Anderson
Executive Vice President of Healthcare Pharmacy Services1.8yrssin datos0.029%
$ 53.2k
4.6yrs
Permanencia media
49yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de SLQT se considera experimentado (4.6 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Timothy Danker
CEO & Director9.3yrsUS$3.49m1.49%
$ 2.7m
Alan Muney
Chief Medical Officer & Member of Healthcare Advisory Board4.2yrssin datossin datos
Donald Hawks
Independent Chairman12.3yrsUS$225.00k0.29%
$ 528.6k
Raymond Weldon
Independent Director12.3yrsUS$207.50k0.29%
$ 528.6k
Christopher Wolfe
Independent Director1.3yrsUS$150.33k0.0054%
$ 9.8k
Denise Devine
Independent Director6.3yrsUS$245.00k0.21%
$ 382.3k
Srdjan Vukovic
Independent Director1.3yrsUS$150.33k0.0054%
$ 9.8k
Earl Devanny
Independent Director6.3yrsUS$225.00k0.21%
$ 374.1k
Kavita Patel
Independent Director5.7yrsUS$215.00k0.21%
$ 374.1k
Rebekah Gee
Member of Healthcare Advisory Board4.2yrssin datossin datos
Basit Chaudhry
Member of Healthcare Advisory Board4.2yrssin datossin datos
Joe Grogan
Member of Healthcare Advisory Board4.2yrssin datossin datos
4.9yrs
Permanencia media
52yo
Promedio de edad

Junta con experiencia: La junta directiva de SLQT se considera experimentada (4.9 años de antigüedad promedio).


Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/20 04:21
Precio de las acciones al final del día2026/05/20 00:00
Beneficios2026/03/31
Ingresos anuales2025/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

SelectQuote, Inc. está cubierta por 12 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Steven ValiquetteBarclays
Steven ValiquetteBarclays
Daniel GrosslightCitigroup Inc